Virus isolates resistant to a variety of structural analogues of oxathiin carboxanilide (UC84) were selected in cell culture and phenotypically and molecularly characterized in order to evaluate the effects of variables in the resistance selection process. The rate of appearance of the resistant viruses and the net loss of sensitivity of the virus isolates to the selecting compound were not dependent on the selective pressure employed against wild-type virus, but were associated with structural features of the compound. Although each of the compounds rapidly selected for resistant viruses, the isolates obtained varied in their overall level of resistance, in their cross-resistance to other non-nucleoside reverse transcriptase inhibitors (NNRTls) and in the amino acid changes present in the reverse transcriptase (RT). The mutation Y181C was most commonly observed, often with a second mutation, such as K101E or V106A. The amino acid change L1001 was also observed upon selection. In order to determine the reproducibility of the in-vitro resistance selection process, 10 isolates resistant to UC84 were independently selected in parallel cultures. Mutations detected in the RT of these isolates were varied but included the commonly reported Y181C and V106A amino acid changes, as well as unique changes K1011, K101N, K103Q, G190A, T1391 and A98S. These results demonstrate that from the heterogeneous wild-type population, antiviral agents, such as the UC compounds, may select a wide variety of virus isolates with resistance-engendering amino acid changes in the RT. In addition, the results also suggest that antiviral agents may select for resistant viruses at different rates and to different extents, offering the possibility that compounds might be
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Introduction
The human immunodeficiency virus type 1 (HIV-1) is entirely dependent upon reverse transcriptase (RT) for replication and productive infection in human cells (Popovic et al., 1984; Barre-Sinoussi et al., 1993; Seki et al., 1995) , rendering the RT a unique and excellent target for antiviral compounds. RT inhibitors which have been approved for clinical use to date include the nucleoside analogues 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxy-3'-thiacytidine (3TC) and 2',3'-didehydro-2',3'-dideoxythymidine (d4T) (Ahluwalia et al., 1987; Yarchoan et al., 1988 Yarchoan et al., , 1989 Mansuri et al., 1989; Schinazi et al., 1992) . Following phosphorylation by host cell enzymes, the nucleoside analogues are incorporated into the viral cDNA by the RT, halting polymerization by RT and virus replication (Mitsuya et al., 1985; Yarchoan et al., 1986; Matthes et al., 1987; St Clair et al., 1987; Reardon and Miller, 1990; Parker et al., 1991) . In contrast, the nonnucleoside RT inhibitors (NNRTI) allosterically inhibit RT activity by reversible binding at a non-substrate binding site on the RT and do not require host cell phosphorylation (Cohen et al., 1991; Nunberg et al., 1991; Condra et al., 1992; Grob et sl., 1992; Jacobo-Molina et al., 1993) . The NNRTI class includes a variety of structurally diverse compounds such as tetrahydro-imidazo[4,5,1-jk] [1,4]-benzodiazepin-2(1H)-one and -thione (TIBO), 1-[(2-hydroxyethoxy)methyl]-6-(phenythio)thymine (HEPT), a series of bis(heteroaryl)piperazines (BHAPs), pyridinone, calanolide A, diphenylsulphone, nevirapine, thiazolobenzimidazole, the benzothiadiazines, and oxathiin carboxanilide (Merluzzi et al., 1990; Pauwels et al., 1990; Bader et al., 1991; Goldman et al., 1991; Romero et al., 1991; Kashman et al., 1992; Klunder et al., 1992; Balzarini et al., 1993; Buckheit et al., 1993 Buckheit et al., , 1994 Maass et al., 1993; McMahon et al., 1993) . Despite the structural diversity of the compounds of this class, all of these inhibitors interact \-8-UClO -'i'-UC10 -frfr UC80 "*UC32 -fr·UC84 * UC38 • UC581 I Fig. 1 . Sensitivity of virus isolates to their respective UC analogues with increasing selective pressure (passage number). EC 5 0 values were obtained using the standard XTT assay and compared with the activity of the compounds against wild-type (1118) virus to calculate fold-resistance. The fold-resistance values obtained for viruses resistant to UC10, UC38 and UC84 were> 285, > 167 and> 140 since they remained inactive against the selecting compound at the IC 5 0 concentration. These values are used as the fold-resistance for these viruses at passage 6.
viruses. The IIIB virus isolate was passaged in the presence of increasing concentrations of each of 10 oxathiin carboxanilide analogues. Initial passage was performed in the presence of twice the EC so concentration of each compound; the concentration of the compound was increased 2-fold with each sequential passage. In this manner the selection pressure, maintained with each compound on the virus, remained identical. While the susceptibility of each virus isolate to AZT remained unchanged (data not shown), the sensitivity of the virus to the selecting compound decreased with increasing passage number, indicating the successful selection of resistant virus with increasing selective pressure (Fig. 1) . These data indicate that following two passages of the IIIB wild-type virus in the presence of each of the UC compounds, four of seven compounds selected for resistant viruses with 5-to 15-fold reduced sensitivity. The remaining three virus populations remained sensitive (less than 5-fold change in sensitivity) to the selecting compound at passage 2. Three additional viruses were not evaluated at intermediate passage due to insufficient quantity of virus. By passage 4, greater levels of resistance were detected with nearly all of the populations and each of the compounds selected for resistant viruses by passage 6. The final foldresistance of each of the resistant virus populations when tested following passage 6 are presented in Table 1 .
Within the time frame utilized for resistance selection, the overall levels of resistance achieved against the different UC compounds was variable among the viral populations. In the data presented in Fig. 1 (Mellors et a/., 1995) .
The emergence of virus populations resistant to nucleoside and non-nucleoside RT inhibitors has been the major obstacle to the use of these compounds in the treatment of HIV-1-infected individuals. Although viral resistance is a critical issue for both nucleoside and non-nucleoside RT inhibitors, the toxicity of the nucleoside inhibitors has also been well documented (Richman et a/., 1987; Yarchoan et a/., 1989) . The low toxicity of NNRTls, even at high concentrations, renders them attractive therapeutic agents. In the study described herein, the effects of the in-vitro drugresistance selection process were evaluated by selecting and characterizing virus populations resistant to a family of NNRTls, derivatives of oxathiin carboxanilide (Bader et al., 1991; Buckheit et a/., 1995c) . This study was prompted by observations of unique biological properties of individual members of this family of compounds (Buckheit et a/., 1995c; Fletcher et a/., 1995a,b) , suggesting the possibility of using several of the compounds in combination with each other or with other RT inhibitors in the treatment of HIV-infected individuals. Structurally similar analogues of oxathiin carboxanilide were studied in order to determine if the structural properties of the inhibitor had a correlative effect on the resistant virus populations which emerge during the selection process. In addition, evaluation of other factors critical to the resistant virus selection process, including the methodology used and the reproducibility of the selection, have been performed and will be discussed.
Results

Anti-H/Vactivity of UC compounds against viruses selected in cell culture
A complete evaluation of the efficacy of the UC compounds against both wild-type and drug-resistant virus populations has been reported (Buckheit et a/., 1995c) . In this report the UC compounds were used to further explore factors important in the selection of drug-resistant "Antiviral activity against wild-type virus as determined in XTT assay (Buckheit et al., 1995c) . 'Therapeuttc index (TI) was determined by division of the IC 5D concentration of the compound by the EC 5 D concentration of the compound.
CAntiviral activity of UC compound against UC-resistant virus isolate (passage 6) selected with the same UC compound. dlC 5 D concentration used to calculate fold-resistance because compound remained inactive at this concentration.
from 5-to 293-fold. Viruses resistant to UC10, UC10, UC38, and UC84 exhibited levels of resistance greater than 140-fold and were completely insensitive to the selecting compound at the highest non-toxic concentration. Although only exhibiting ",36-fold resistance, the UC69-resistant virus was also completely insensitive to UC69 at the highest non-toxic concentration evaluated, indicating this virus was highly resistant. The remaining resistant viruses, selected with UC32, UC51, UC68, UC80 and UC581, exhibited 5-to 58-fold loss of sensitivity to the selecting compound. With these populations, protection was eventually achieved, although at higher concentrations of the compound.
Although several of the UC compounds remained active against drug-resistant viruses at higher concentrations, it is also important to consider the effect of resistance on the therapeutic index (TI) for each of these compounds. IC 5 0 and TI values reported in Table 1 provide an indication of the narrowing of the TI for each compound upon selection of the resistant virus. Only UC68 had an appreciable therapeutic index (>100) when evaluated against the UC68-resistant virus (Table 1 ). The remaining active compounds (UC32, UC51, UC80 and UC581) exhibited therapeutic indices of ",10-20 when evaluated against the resistant virus populations. With many of the UC compounds, the selection of a resistant virus for six passages resulted in the complete loss of antiviral activity and therapeutic index (UC10, UC38, UC69, UC10 and UC84). To determine if the overall level of resistance of a virus was a phenotypic property of the virus or of the compound, a virus population selected for resistance against each of the compounds was evaluated against all of the parental compounds used to select the viruses. The results of this comparison (Table 2) show that the level of cross-resistance varied with each virus and was dependent on the compound. For example, UC68 ranged from 1-to 28-fold less active against each of the UC-resistant viruses compared to its activity against wild-type HIV-1. Resistance to UC10 and UC10 showed marked specificity to the viruses selected with these compounds, although all of the viruses exhibited some level of cross-resistance to these analogues. In contrast, all of the viruses exhibited substantial resistance to UC69, UC51 and UC38. Conversely, when evaluating the activity of the group of UC compounds against any single virus, a wide range of cross-resistance was observed. For example, although UC68 and UC10 are very similar in structure, UC10 uc compound/Fold-resistant UC-resistant  Amino acid  isolate  change  UC10  UC68  UC69  UC57  UC38  UC70   UC10-R  K101EIY181C  243  27  >36  535  >167  34  UC38-R  Y181C  19  8  >36  53  >167  9  UC57-R  K101E1Y181C  34  9  >36  133  >167  16  UC68-R  Y181C  16  7  >36  40  80  6  UC69-R  V1061IY181C  16  8  >36  50  >167  <4  UC70-R  L1001  53  28  >36  >2500  >167  215   Table 2 . Cross-resistance phenotype of UCresistant virus isolates "Fold resistance determined by division of EC so concentration of UC compound against UC-resistant isolate by EC so concentration of UC compound against wild-type isolate.
selected a virus population which was substantially resistant to both compounds, while UC68 selected a much less resistant population.
Molecular characterization of UG-resistant virus populations
The RT gene of each resistant virus was sequenced to identify the specific resistance-engendering amino acid changes. The codon and corresponding amino acid changes identified in the RT of the resistant viruses have been previously presented (Buckheit et al., 1995c) . The amino acid changes are presented in Table 1 . Several different amino acid changes in the viral RT were selected by the UC analogues, including Y181C, K101E, V106A, and L1001. Sequence analysis of the RT region of the resistant viruses provided the expected molecular rationale for biological cross-resistance data which was used to group these viruses. The definition of four subgroups of NNRTI-resistant viruses which are defined by the amino acid change present in the RT and its cross-resistance phenotype have been previously reported (Buckheit et al., 1995a) . Each of the 10 virus isolates resistant to the respective UC compounds were also resistant to E-BPTU, another NNRTI. All but one isolate remained sensitive to the NNRTI costatolide (data not shown). Based on these cross-resistance data, nine of the viruses were defined as Group III NNRTI-resistant viruses (Buckheit et al., 1995a) and upon molecular characterization all were found to possess the expected Y181C mutation. The remaining resistant virus (UC70-resistant) was classified as a Group I virus based upon its cross-resistance to E-BPTU, costatolide, and UC70. Upon sequencing the UC70-resistant isolate, the L1001 mutation was identified. Complete characterization of these resistant populations against a large panel of NNRTls has been reported (Buckheit et al., 1995c) . In some cases virus subpopulations containing more than one mutation were selected. For example, the virus resistant to UC69 possessed both the Y181C and the V1061 mutation. The V1061 mutation did not alter the resistance phenotype or the overall level of resistance (Table 1) associated with the Y181C mutation. In addition, the viruses resistant to UC57 and UC10 possessed both the K101E and Y181C mutations and both isolates remained sensitive to costatolide. In general, the isolates with both the K101E and Y181C mutations were found to exhibit higher levels of cross-resistance to other NNRTls than isolates possessing only the Y181C mutation ( Table 2) .
Reproducibility of the resistance selection process
To examine the reproducibility of the resistance selection method, 10 virus populations resistant to UC84 were independently selected in parallel cell cultures. The viruses were selected in the presence of gradually increasing concentrations of UC84, reaching a maximum concentration of 28 J.lM. After five passages, the viruses were evaluated for sensitivity to UC84. Each of the viruses obtained was resistant to UC84 at the highest non-toxic concentration evaluated, yielding> 270-fold resistance to the compound following five passages (Table 3) .
Sequencing data presented in Table 3 indicate that each of the 10 viruses possessed the Y181 C mutation. In addition, nine of the viruses possessed at least one additional amino acid change. The virus designated U5 contained four additional changes while U7 contained two additional changes. Eight of the virus populations possessed mutations which resulted in several different amino acid changes clustered in the amino acid range 98-106, including A98S, K1011, K101N, K1OH, K1030 and V106A. The U5 virus possessed the T1391 amino acid change previously identified as yielding resistance to calanolide A (Buckheit et al., 1995a) . The remaining amino acid changes identified in these viruses included Y181C, L187F, and G190A. In addition, a UC84-resistant virus which contained the L1001 mutation has been previously reported (Buckheit et al., 1995a) . Three distinct mutations were found at position 101; two of these mutations (K101Nand K10H) have not been previously reported. The mutations A98S and K1030 similarly have not been reported. The oxathiin carboxanilide class of compounds comprises a number of highly potent and non-cytotoxic inhibitors of HIV-1 replication (Balzarini et al., 1995; Buckheit et al., 1995c) . As is the case with all of the NNRTls described to date, resistant viruses were rapidly selected by UC compounds in cell culture. In consideration of the time frame in which resistance was seen, these data are consistent with previously published results which have indicated that the selection of viruses resistant to other NNRTls occurs within three to six passages with gradually increasing drug concentration. The high levels of variability associated with the overall fold-resistance of these viruses indicates that some compounds in this class may select for resistant virus at a slower rate; cross-resistance data using highly resistant and slightly resistant viruses support this possibility and suggest that compounds may be chosen which do not readily yield highly resistant virus populations. Our data suggest that relatively minor chemical changes in the antiviral compound affect the resistance phenotype of the selected virus populations.
Variables in the selection of NNRTI-resistant viruses 26S
From the results obtained to date, no correlation has been determined to exist between the selective pressure (i.e. fold-increase in drug concentration relative to the EC so concentration) of the UC compound and the level of resistance observed with the selected populations. For example, UC68, with an EC so value of 0.04 J..lM, selected for a resistant virus which displayed only S-fold resistance, whereas UClO, which exhibited an EC so concentration of 0.1 J..lM, selected for a 293-fold resistant virus. Since the selective pressure maintained during each passage was similar with each of the various compounds, the wide spread of fold-resistance values achieved with this group of compounds suggests that factors other than selective pressure are critical to the fold-resistance achieved. Correlation between the structural motifs of these UC compounds and overall level of resistance could also not be readily determined from these data. The mechanism responsible for these differences in overall resistance should be resolved in order to define the structural features of the compounds which effect their binding to the non-nucleoside RT inhibitor binding pocket and result in the selection of highly resistant or slightly resistant viruses.
A variety of distinct mutations present in the RT gene resulted in reduced sensitivity of the UC-resistant viruses to the selecting compound (Buckheit et el., 1995c) . The UC compounds evaluated in this study selected for the amino acid changes L1001, K1 01E, V106A, and Y181C. In contrast, another set of similar UC compounds has been reported to select resistant viruses containing E138K, L1001, K1011/E, K103T/D and G141E amino acid substitutions (Balzarini et al., 199S) . Although the Y181C mutation was by far the predominant mutation identified in our studies, this mutation was not observed by Balzarini et al. suggesting significant differences in the selection methodology used or differences in the respective wild-type virus pools. The mutations identified in both of these studies have been previously identified in vitro and in vivo by other investigators (Mellors et al., 1995) .
Separate virus cultures subjected to selection with the same concentration of UC84 yielded resistant viruses with a number of different amino acid changes. These data indicate that a given antiviral compound may not consistently select for one specific mutation, even when using identical culture conditions. Instead, varying and/or multiple mutations may be selected during the resistance selection process. Similar results have been obtained from in-vitro and in-vivo assays and the results have been ascribed to differences in the selection process utilized (Balzarini et al., 1994; Buckheit et al., 1995b) . For example, as discussed, Balzarini et al. (199S) reported mutations at amino acids 138, 100, 101, 103 and 141 with a set of UC compounds. Reproduction of the selection method used by the Balzarini group in our laboratory and using compounds available in both laboratories (UC84, UC38 and UC10) resulted in viruses with amino acid changes
Y181 C or Y181 C plus V1081 with all three compounds (data not shown). UC84 also selected an additional virus which possessed the Y188H mutation (data not shown). Since both our results and those reported by Balzarini et al. were obtained using CEM cells and the IIIB strain of virus for the selection of resistant virus populations, other factors must be important in the selection process. Since the resistant viruses obtained probably represent the isolates present in the greatest frequency in the wild-type virus pool, differences in results between our groups may result from differences in the genetic composition of our respective wild-type virus pools. It is possible that continued resistance selection would result in the disappearance of mutations from these virus populations, altering the cross-resistance phenotype of the resistant population. It has been previously reported that continued selection of resistant virus may result in sequential amino acid changes in the RT (Balzarini et al., 1994) . In our UCtreated cultures, the Y181 C mutation emerged first; additional mutations were observed in later passages (data not shown). Attempts to determine if the initial Y181 C mutation was lost with increased selection pressure beyond passage 6 have not yet been made.
In summary, virus populations resistant to UC compounds were rapidly selected in cell culture; these virus populations possessed a wide range of fold-resistance to the selecting UC compounds. These data indicate that small chemical changes in the structure of the compound sometimes resulted in large changes in overall fold-resistance of the population to the selecting compound, independent of the selective pressure employed. It appears that certain NNRTls may select for viruses with a 'low resistance' phenotype, while others select for a 'high resistance' phenotype. The chemical features of the compounds which result in these distinct phenotypes should be identified and exploited in the drug development process.
Materials and Experimental Procedures
Cells and virus
The CEM-SS cell line (Nara and Fischinger, 1988 ) and the HIV-1 11 18 virus isolate were obtained from NIAID AIDS Research and Reference Reagent Program (Bethesda, MD, USA). The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 U mL-1 ) , and streptornyclnrtoo I1g mL-1 ) .
Antiviral compounds
The antiviral compounds used in this study were submitted by the Uniroyal Chemical Company, Inc. (Guelph, Ontario, Canada) to the National Cancer Institute's AIDS antiviral screening program, and were found active against HIV-1 ( Buckheit et al., 1995c) . The chemical structure of the compounds has been described previously (Buckheit et el., 1995c) .
Reagents
The nucleotide composition of the primers used for the PCR amplification and the sequencing reactions of the RT of the UCresistant virus isolates were as follows: Polymerase chain reaction methodology was used to amplify the viral RT gene, using the Boehringer Mannheim PCR Core Kit (Mannheim, Germany). Materials required for the performance of tissue culture and anti-HIV assays have been previously described . Acrylamide, N,Nmethylene-bisacrylamide, N,N,N',N-tetramethylenediamine (TEMED), ammonium persulphate and urea were purchased from Sigma Chemical Company (St Louis, MO, USA). Other molecular analysis reagents, including the a_ 3 S S deoxy-ATP (1000 Ci/mMol), glycerol-tolerant buffer and the USB Sequenase PCR Product Sequencing Kit, were purchased from Amersham (Cleveland, OH, USA).
Anti-HIV assay
Antiviral activity of the compounds was determined using the microtitre XTT assay as previously described . Antiviral data are reported as the concentration of drug required to inhibit 50% of virus induced cell killing or virus production (EC so ) . Concentrations of the compounds which inhibit cellular growth by 50% are also reported (IC so ) .
Selection of drug resistant viruses
Resistant virus populations were selected as previously described (Buckheit et al., 1995a,b) . The viruses were evaluated to determine fold-resistance at two-passage intervals, up to and including passage 6, employing the anti-HIV assay described. Fold-resistance was calculated as the EC so concentration of the compound determined against the resistant virus divided by the EC so concentration of the compound determined against the wild-type IIIB virus. A virus population was defined as resistant if this ratio exceeded five.
Analysis of RT mutations
Genomic DNA was isolated from acutely infected CEM-SS cells using selective resin column chromatography (Qiagen, Chatsworth, CA, USA). The first 780 bp of the HIV-1 reverse transcriptase gene was then amplified from the resulting genomic DNA using standard polymerase chain reaction (PCR) methodology. Briefly, samples were subjected to 35 rounds of amplification in a 100 III reaction mixture containing 1 Ilg genomic DNA, 10 mM Tris-HCI, pH 8.3, 50 mM KCI, 1.5 mM MgCI 2 , 200 IlM each of dATP, dCTP, dGTP, and dTTP, 0.3 11M BlA-A (forward primer), 0.3 IlM NE1-A (reverse primer), and 2.5 U Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN, USA). PCR amplification conditions consisted of an initial DNA denaturation step at 95°C for 5 min followed by 35 cycles of 95°C for 1 min, 55°C for 1.5 min, and 72°C for 1.75 min; all samples were held at 72°C for 10 min upon completion of the thermocycling programme. Twenty microlitres of each PCR reaction mixture was resolved by electrophoresis on 1% agarose gels with DNA molecular weight size standards to confirm amplification of appropriately sized PCR product.
The PCR-amplified DNA products were subsequently sequenced directly using eight overlapping primer oligonucleotides and the Sequenase PCR Product Sequencing Kit (USB-Amersham, Cleveland, OH, USA) per the manufacturer's instructions. The RT nucleotide sequences obtained from the drug-resistant virus isolates were compared to the parental HIV-1 I1J B sequence using the UWGCG suite of DNA sequence analysis software (Version 8, Genetics Computer Group).
